Reproductive Medicine Center, Department of Obstertrics and Gynecology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Center for Reproductive Medicine, Maternal and Child Health Hospital in Xuzhou, Xuzhou Medical University, Xuzhou, China.
J Med Virol. 2024 Mar;96(3):e29468. doi: 10.1002/jmv.29468.
Cervical human papillomavirus (HPV) infection is believed to increase the risks of pregnancy failure and abortion, however, whether the uterine cavity HPV infection reduces pregnancy rate or increases miscarriage rate remains unclarified in infertile women undergoing assisted reproductive technology (ART) treatment. Therefore, we aimed to assess ART outcomes in the presence of intrauterine HPV. This was a hospital-based multicenter (five reproductive medicine centers) matched cohort study. This study involved 4153 infertile women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection treatment in five reproductive medicine centers between October 2018 and 2020. The spent embryo transfer media sample with endometrium tissue were collected and performed with flow-through hybridization and gene chips to detect HPV DNA. According to basic characteristics, HPV-positive and negative patients were matched in a ratio of 1:4 by age, body mass index transfer timing, transfer type, and number of embryos transferred. The primary outcome was pregnancy and clinical miscarriage rates in the transfer cycle underwent HPV detection. 92 HPV-positive and 368 HPV-negative patients were screened and analyzed statistically. Univariate analysis showed uterine cavity HPV infection resulted in lower rates of ongoing pregnancy (31.5% vs. 44.6%; p = 0.023), implantation (32.3% vs. 43.1%; p = 0.026), biochemical pregnancy (47.8% vs. 62.5%; p = 0.010), and clinical pregnancy (40.2% vs. 54.3%; p = 0.015) compared with HPV negative group. The infertile female with positive HPV also had a slightly higher frequency of biochemical miscarriage (15.9% vs. 13.0%; p = 0.610) and clinical miscarriage (24.3% vs. 15.5%; p = 0.188). These findings suggest that HPV infection in the uterine cavity is a high risk for ART failure. HPV screening is recommended before ART treatment, which may be benefit to improving pregnancy outcome.
人乳头瘤病毒(HPV)感染被认为会增加妊娠失败和流产的风险,然而,在接受辅助生殖技术(ART)治疗的不孕女性中,宫腔 HPV 感染是否会降低妊娠率或增加流产率仍不清楚。因此,我们旨在评估宫腔 HPV 存在时的 ART 结局。
这是一项基于医院的多中心(5 个生殖医学中心)匹配队列研究。这项研究涉及 2018 年 10 月至 2020 年期间在 5 个生殖医学中心接受体外受精(IVF)或胞浆内精子注射治疗的 4153 名不孕妇女。采集子宫内膜组织的废弃胚胎移植介质样本,进行流式杂交和基因芯片检测 HPV DNA。根据基本特征,HPV 阳性和阴性患者按年龄、体重指数、移植时机、移植类型和移植胚胎数量的比例 1:4 进行匹配。主要结局是在接受 HPV 检测的移植周期中的妊娠和临床流产率。筛选并统计了 92 例 HPV 阳性和 368 例 HPV 阴性患者。单因素分析显示,宫腔 HPV 感染导致持续妊娠率(31.5% vs. 44.6%;p=0.023)、种植率(32.3% vs. 43.1%;p=0.026)、生化妊娠率(47.8% vs. 62.5%;p=0.010)和临床妊娠率(40.2% vs. 54.3%;p=0.015)均降低。HPV 阳性的不孕女性生化流产率(15.9% vs. 13.0%;p=0.610)和临床流产率(24.3% vs. 15.5%;p=0.188)也略有升高。
这些发现表明宫腔 HPV 感染是 ART 失败的高危因素。建议在 ART 治疗前进行 HPV 筛查,这可能有助于改善妊娠结局。